The Research and Development chief of Nektar Therapeutics has executed a sale of company shares valued at $13,036. This transaction has been disclosed in accordance with regulatory requirements. The sale reflects the ongoing activities of company executives in managing their personal investment portfolios. Further details regarding the timing and specific number of shares sold have not been provided.
Don't miss out on breaking stories and in-depth articles.
